Poolbeg Pharma plc
Poolbeg Pharma plc is a clinical-stage, pre-revenue UK biopharmaceutical company focused on transforming cancer immunotherapy. Its lead asset POLB 001, an orally delivered p38 MAPK inhibitor, is being developed as a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company is also developing an oral encapsulated GLP-1 programme for obesity with partner AnaBio, and is exploring AI-led drug discovery collaborations.
FY2025 in sixty seconds
year to 31 Dec 2025 · approved 27 Apr 2026 · 64 pages · Companies House
Poolbeg Pharma plc is a UK drug developer working on a pill to prevent a dangerous immune over-reaction that some cancer treatments can cause, plus an oral obesity treatment. It has no products on sale and earned no revenue in either year. Its loss after tax narrowed slightly to £5.7m, from £5.8m the year before. The report points to cost-saving steps during the year, including some job cuts, though research spending rose to £1.5 million from £1.4 million. One-off costs were small, such as writing down research projects that have been set aside.
Cash at the year end was £7.7m, against £7.8m a year earlier, and the company has no borrowings. Cash held up because the company raised £4.5m by selling new shares in June 2025. No dividend is proposed.
Management expects early results from its cancer trial in summer 2026 and plans to start the obesity trial in the second half of the year. It hopes good results will attract partners. The auditors raised no doubts about the company's ability to keep going, though the report warns that trials may fail and that more funding may not be available.
Targeted operational efficiency measures including selective headcount reductions implemented during the year to streamline the cost base
To ensure resources remain aligned with near-term development priorities, the Company implemented targeted operational efficiency measures during the year, including selective headcount reductions.
page 3We remain focused on delivering important milestones, namely interim data from the POLB 001 clinical trial in the summer, ahead of full data, and the commencement of the oral GLP-1 proof-of-concept trial, expected in H2 2026.
page 4R&D expenses increased year-on-year
R&D expenses of £1.5 million (2024: £1.4 million)
page 35 years on one page · FY2021–FY2025
| Line | FY2021locked | FY2022locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|
| Operating profit | |||||
| Profit for the year | |||||
| Basic EPS | |||||
| Free cash flow | |||||
| Net debt (negative = net cash) | |||||
| Shares in issue | |||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
Nothing restated
Every figure is read again from the following year’s report: 110 confirmed, 1 differ.
No figure has been restated: every figure a later report printed again, it printed the same.